Results 11 to 20 of about 18,490 (188)

Chemical generation of bispecific antibodies [PDF]

Proceedings of the National Academy of Sciences, 2010
Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stability and manufacturing complexity.
Jie Huang, Bryan Oates, Curt W. Bradshaw, Michael J. Shields, Bin Liu, Richard A. Lerner, Joselyn Del Rosario, Crystal Hagen, Dingguo Liu, Lingna Li, Ping Jin, Michelle Parish, Robert E. Murphy, Gary Woodnutt, Jing-Yu Lai, Joel Desharnais, Marla J. Matin, Zemeda W Ainekulu, Abhijit Bhat, Nancy Levin, Venkata Doppalapudi, Rodney W. Lappe   +21 more
openaire   +3 more sources

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Engineering CAR‐T Therapeutics for Enhanced Solid Tumor Targeting

Advanced Materials, EarlyView.
CART cell therapy has proven effective for blood cancers but struggles with solid tumors due to diverse antigens and complex environments. Recent efforts focus on improving CAR design and validation platforms. Advances in protein engineering, machine learning, and organoid systems aim to enhance CAR‐T therapy against solid tumors.
Danqing Zhu, Won Joon Kim, Hyunjin Lee, Xiaoping Bao, Pilnam Kim   +4 more
wiley   +1 more source

Macrocyclic Peptide Probes for Immunomodulatory Protein CD59: Potent Modulators of Bacterial Toxin Activity and Antibody‐Dependent Cytotoxicity

Angewandte Chemie, EarlyView.
This study presents novel macrocyclic peptides with low nanomolar affinity for CD59, an immunomodulatory cell surface receptor associated with human disease. Crystallographic and structure‐activity relationship (SAR) studies reveal peptide CP‐06 mimics the binding of biologically relevant CD59 interaction partners. Dimeric and lipidated CP‐06 analogues
Jasmine K. Bickel, Ammar. I. S. Ahmed, Aidan B. Pidd, Rhodri M. Morgan, Tom E. McAllister, Sam Horrell, Emma C. Couves, Hemavathi Nagaraj, Edward J. Bartlett, Kamel El Omari, Akane Kawamura, Doryen Bubeck, Edward W. Tate   +12 more
wiley   +2 more sources

Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators. [PDF]

Cancer Med
ABSTRACT Background Preliminary data from the MorningSun study have demonstrated that outpatient subcutaneous mosunetuzumab can be safely administered. Aims This publication describes how community centers in the MorningSun phase 2 study of outpatient subcutaneous mosunetuzumab in B‐cell non‐Hodgkin lymphomas prepared workflow and logistics (staff ...
Graff T, Flinn I, Sharman JP, Liu S, Anz BM, Gandhi M, Ayed A, Zuniga R, Mansoor AH, Cassoli LM, Wu M, Jani P, Biondo JML, Lin T, Burke JM.   +14 more
europepmc   +2 more sources

Bioorthogonal Reaction of o‐Quinone with Furan‐2(3H)‐One for Site‐Selective Tyrosine Conjugation and Construction of Bispecific Antibody Complexes

Advanced Science, EarlyView.
A site‐selective, efficient, and mild tyrosine conjugation via tyrosinase oxidation and nucleophilic addition, allowing for site‐selective functionalization of peptides, recombinant proteins, and IgGs. Site‐selective mono‐functionalization of IgGs at Y296 enables the construction of immunoliposomes.
Hongfei Chen, Zhiyi Xu, Yishu Bao, Farshad Shiri, Dingdong Yuan, Yuke Hu, Biquan Li, Bin Zeng, Xiaojing Li, Hao Kong, Zikang Wang, Wilson Chun‐Yu Lau, Zhenyang Lin, Jiang Xia   +13 more
wiley   +1 more source

Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology

Angewandte Chemie, EarlyView.
Targeted protein degradation (TPD) has emerged as a powerful therapeutic approach, with numerous candidates molecules now advancing into clinical development. Recent innovations have incorporated nanoparticles to facilitate and enhance these degradation processes, yielding synergistic effects.
Andrew G. Baker, Adrian Pui Ting Ho, Laura S. Itzhaki, Ljiljana Fruk   +3 more
wiley   +2 more sources

Recent Advances in mRNA Delivery Systems for Cancer Therapy

Advanced Science, EarlyView.
This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang, Ya‐Nan Fan, Si‐Qi Jiang, Ya‐Jing Ma, Yao‐Ru Yu, Yu‐Xin Qing, Qian‐Ru Li, Yi‐Lin Liu, Song Shen, Jun Wang   +9 more
wiley   +1 more source

Enhancing the Protein Stability of an Anticancer VHH‐Fc Heavy Chain Antibody through Computational Modeling and Variant Design

Advanced Science, EarlyView.
In this study, a computational pipeline is developed to systematically evaluate the conformational stability, disulfide bond reduction state, and aggregation and degradation tendencies of an anticancer VHH‐Fc fusion antibody. Based on the mechanistic insights, antibody variants with enhanced stability and increased yield are successfully designed. This
Yuan Fang, Menghua Song, Tianning Pu, Xiaoqing Song, Kailu Xu, Pengcheng Shen, Ting Cao, Yiman Zhao, Simon Hsu, Dongmei Han, Qiang Huang   +10 more
wiley   +1 more source

An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy

Advanced Science, EarlyView.
This study develops a dimeric T cell receptor engager protein specific for tumor KRAS‐G12V mutation. The engager proteins are capable of mediating the formation of synapse between T cell and tumor cell and demonstrate substantial tumor suppression efficacy.
Keke Ma, Jie Wang, Min Jiang, Juanhua He, Fangyang Li, Dan Lu, Chao Su, Yan Chai, Wenjing Jin, Yu Chen, Catherine W.H. Zhang, Xiaopeng Ma, Hui Tan, George F. Gao, Shuguang Tan   +14 more
wiley   +1 more source